Drug General Information
Drug ID	D0A6VD
Former ID	DIB015884
Drug Name	VS-4718
Indication	Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]		Phase 1	[524282]
Company	Verastem
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Focal adhesion kinase	Target Info	Inhibitor	[532800]
KEGG Pathway	ErbB signaling pathway
	Chemokine signaling pathway
	PI3K-Akt signaling pathway
	Axon guidance
	VEGF signaling pathway
	Focal adhesion
	Leukocyte transendothelial migration
	Regulation of actin cytoskeleton
	Bacterial invasion of epithelial cells
	Amoebiasis
	Pathways in cancer
	Transcriptional misregulation in cancer
	Proteoglycans in cancer
	Small cell lung cancer
PANTHER Pathway	Angiogenesis
	Integrin signalling pathway
	VEGF signaling pathway
	CCKR signaling map ST
Pathway Interaction Database	LPA receptor mediated events
	CXCR4-mediated signaling events
Reactome	Apoptotic cleavage of cellular proteins
	Regulation of actin dynamics for phagocytic cup formation
	Integrin alphaIIb beta3 signaling
	GRB2:SOS provides linkage to MAPK signaling for Integrins
	p130Cas linkage to MAPK signaling for integrins
	NCAM signaling for neurite out-growth
	Signal regulatory protein (SIRP) family interactions
	EPHB-mediated forward signaling
	EPHA-mediated growth cone collapse
	DCC mediated attractive signaling
	Netrin mediated repulsion signals
	VEGFA-VEGFR2 Pathway
	RHO GTPases Activate WASPs and WAVEs
	RAF/MAP kinase cascade
WikiPathways	Regulation of Actin Cytoskeleton
	EGF/EGFR Signaling Pathway
	TGF beta Signaling Pathway
	Signaling of Hepatocyte Growth Factor Receptor
	Focal Adhesion
	Apoptosis-related network due to altered Notch3 in ovarian cancer
	Nanoparticle-mediated activation of receptor signaling
	JAK/STAT
	Primary Focal Segmental Glomerulosclerosis FSGS
	Alpha 6 Beta 4 signaling pathway
	Corticotropin-releasing hormone
	Leptin signaling pathway
	RANKL/RANK Signaling Pathway
	Netrin-1 signaling
	NCAM signaling for neurite out-growth
	Integrin-mediated Cell Adhesion
	Integrin alphaIIb beta3 signaling
	Apoptotic execution phase
	Angiogenesis
	Androgen receptor signaling pathway
References
Ref 524282	ClinicalTrials.gov (NCT01849744) Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies. U.S. National Institutes of Health.
Ref 532800	FAK Inhibition disrupts a beta5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther. 2014 Aug;13(8):2050-61.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.